LOGIN
ID
PW
MemberShip
2025-05-16 01:45
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
AbbVie¡¯s workforce¡è MSD¡é due to business restructuring
by
Son, Hyung Min
Apr 24, 2025 06:01am
Various factors, including the sale of drug rights, early retirement programs (ERP), and the launch of new drugs, have affected the number of employees at Korean subsidiaries of multinational pharmaceutical companies. AbbVie Korea doubled its workforce over 4 years through the Allergan merger. BMS Korea, Merck, and Novo Nordisk Korea saw signifi
Company
'One year anniversary of Adtralza's launch in KOR'
by
Son, Hyung Min
Apr 23, 2025 06:12am
Adtralza, which debuted in the market last year, has been shown to improve the quality of life for atopic dermatitis patients during its first year of domestic launch. Experts note that its effectiveness in areas such as the head and neck, where symptoms are more visible, could lead to broader applications. On the 22nd, LEO Pharma held a
Company
Multinational pharma's ave. salaries amount to KRW 100m
by
Son, Hyung Min
Apr 22, 2025 05:59am
Last year, the average annual salary for employees at the Korean subsidiaries of major multinational pharmaceutical companies surpassed KRW 100 million, with Sanofi&8209;Aventis Korea and Gilead Sciences Korea close to KRW 150 million. According to an analysis of the 2023 audit reports filed by 30 foreign pharma subsidiaries on the Financial
Company
Darzalex SC may be prescribed at general hospitals in KOR
by
Eo, Yun-Ho
Apr 22, 2025 05:59am
The subcutaneous injection formulation of the multiple myeloma drug Darzalex may now be prescribed at general hospitals in Korea. According to industry sources, Janssen Korea's Darzalex SC (daratumumab) has passed the drug committees (DCs) of tertiary hospitals in Korea, such as the Seoul National University Hospital and Seoul Asan Medica
Company
Can 'indication-based pricing' become a reality?
by
Moon, sung-ho
Apr 22, 2025 05:58am
With the presence of anti-cancer drugs in the clinical field becoming more prominent in recent years, multinational pharmaceutical companies have been calling for a new reimbursement system. In addition to existing immuno-oncology drugs, the emergence of antibody-drug conjugates (ADCs) has increased the number of treatments that are effective
Company
Zuellig Pharma's performance fluctuates after a brief reboun
by
Son, Hyung Min
Apr 21, 2025 05:54am
Zuellig Pharma Korea, a global pharmaceutical distributor that had experienced ups and downs in its external growth, successfully rebounded last year. Zuellig Pharma's sales declined for 4 consecutive years after recording sales of over KRW 1 trillion in 2020 but showed signs of recovery by taking on the domestic distribution of new drugs from m
Company
Sanofi¡¯s MenQuadfi to be launched soon in Korea
by
Whang, byung-woo
Apr 21, 2025 05:54am
Sanofi's next-generation meningococcal vaccine is set to launch just 1 year after receiving approval in Korea, signaling the start of intense market competition. According to industry sources, Sanofi is preparing to launch its invasive meningococcal disease vaccine MenQuadfi in the third quarter of this year. MenQuadfi is a fully liqui
Company
Roche Korea's 'Lunsumio' available at general hospitals
by
Eo, Yun-Ho
Apr 21, 2025 05:54am
The first GIFT-designated drug 'Lunsumio' can now be prescribed in general hospitals. According to industry sources, Roche Korea's CD20xCD3 bi-specifc antibody 'Lunsumio (mosunetuzumab)' has passed the drug committee (DC) of Asan Medical Center in Seoul. Lunsumio is the first medicine to be designated as a 'Global Innovative products
Company
Hope for polycythemia vera, Besremi, makes reimb progress
by
Eo, Yun-Ho
Apr 21, 2025 05:53am
Industry attention is gathering on the insurance reimbursement progress for the polycythemia vera treatment, Besremi. According to industry sources, PharmaEssentia Korea's new drug for polycythemia vera, Besremi (ropeginterferon alfa-2b-njft), has been determined cost-effective by the Health Insurance Review and Assessment Service's Pharm
Company
Vocabria+Rekambys may be prescribed in general hospitals
by
Eo, Yun-Ho
Apr 18, 2025 05:59am
The long-acting HIV drug Vocabria+Rekambys combination therapy may now be prescribed in general hospitals in Korea. According to industry sources, GSK Korea¡¯s Vocabria (cabotegravir) and Janssen Korea¡¯s Rekambys (rilpivirine) combination passed the drug committees (DCs) of various medical institutions in Korea, including Korea Universit
1
2
3
4
5
6
7
8
9
10
>